ACA
PRTK

Anchor Capital Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Anchor Capital Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-8,000
Closed -$206K – 293
2015
Q2 		$206K Buy
+8,000
New +$227K ﹤0.01% 282

Other funds holding PRTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Anchor Capital Advisors's PRTK Position: Q3 2015 in Review

Anchor Capital Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2015, closing a stake of 8,000 shares — an estimated $206K sold.

Anchor Capital Advisors first reported a position in PRTK in Q2 2015 and held it in 1 quarter. The position peaked at $206K in Q2 2015. 60 funds tracked by Wall St. Rank hold PRTK as of Q3 2015.

  • Anchor Capital Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Anchor Capital Advisors sold 8,000 Paratek Pharmaceuticals, Inc. shares in Q3 2015, an estimated $206K.
  • Anchor Capital Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Anchor Capital Advisors's Paratek Pharmaceuticals, Inc. position peaked at $206K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2015.

Based on Anchor Capital Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.